Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy
- PMID: 19915448
- PMCID: PMC2844503
- DOI: 10.1097/QAD.0b013e32832e5303
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy
Abstract
Background: Pregnancy-limited antiretroviral therapy (PLAT) drastically reduces HIV-1 transmission to the newborn, but may select for antiretroviral drug resistance mutations in mothers.
Methods: We evaluated antiretroviral-naive, HIV-1-infected pregnant women who received PLAT between 1998 and 2005, and had 2-month or 6-month postpartum plasma samples available with HIV-1 RNA levels more than 500 copies/ml. Postpartum drug resistance mutation rates were assessed blindly using population sequencing and allele-specific PCR (ASPCR) of the M184V, K103N and D30N mutations. Factors associated with selection of drug resistance mutations were investigated.
Results: One hundred and forty-six women were included. All women received zidovudine and lamivudine during pregnancy; 76% also received nelfinavir and 8.2% nevirapine. Resistance data were available from 114 women (78%). Postpartum rates of single-class, dual-class, and triple-class resistance were, respectively, 43, 6.1 and 0% (63.2, 10.5 and 1.7% by ASPCR). In women receiving dual or triple PLAT, respectively, postpartum M184V/I rates were 65% (95% by ASPCR) and 28.7% (51.6% by ASPCR), respectively (P < 0.01). Postpartum nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance rates among women receiving nevirapine were 25% for K103N (37.5% by ASPCR) and 12.5% for Y188C. Protease inhibitor resistance rates in women receiving nelfinavir were 1.1% for D30N (1.1% by ASPCR) and 1.1% for L90M. Dual versus triple PLAT and prolonged zidovudine exposure were associated with selection of M184V. Nevirapine use and length of zidovudine and lamivudine exposure were associated with selection of K103N.
Conclusion: PLAT is associated with frequent selection of resistance to drugs with low-genetic barrier. Triple-drug PLAT decreases the odds for M184V selection. Routine postpartum genotypic resistance testing may be useful to guide future treatment decisions in mothers.
Similar articles
-
Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.AIDS Res Hum Retroviruses. 2007 Dec;23(12):1515-20. doi: 10.1089/aid.2007.0025. AIDS Res Hum Retroviruses. 2007. PMID: 18160009
-
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.AIDS. 2005 Jan 3;19(1):63-7. doi: 10.1097/00002030-200501030-00007. AIDS. 2005. PMID: 15627034
-
HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.PLoS Med. 2011 Mar;8(3):e1000430. doi: 10.1371/journal.pmed.1000430. Epub 2011 Mar 29. PLoS Med. 2011. PMID: 21468304 Free PMC article. Clinical Trial.
-
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.Clin Drug Investig. 2006;26(11):611-27. doi: 10.2165/00044011-200626110-00001. Clin Drug Investig. 2006. PMID: 17163296 Review.
-
Genotypic resistance tests for the management of the HIV-infected pregnant woman.Scand J Infect Dis Suppl. 2003;106:70-4. Scand J Infect Dis Suppl. 2003. PMID: 15000589 Review.
Cited by
-
Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa.BMC Infect Dis. 2020 Jul 22;20(1):532. doi: 10.1186/s12879-020-05255-5. BMC Infect Dis. 2020. PMID: 32698772 Free PMC article.
-
Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes.J Infect Dis. 2013 Jun 15;207 Suppl 2(Suppl 2):S93-100. doi: 10.1093/infdis/jit110. J Infect Dis. 2013. PMID: 23687295 Free PMC article. Review.
-
No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572-7. doi: 10.1097/QAI.0b013e31829308f8. J Acquir Immune Defic Syndr. 2013. PMID: 23542639 Free PMC article. Clinical Trial.
-
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):542-50. doi: 10.1097/QAI.0000000000000072. J Acquir Immune Defic Syndr. 2014. PMID: 24759064 Free PMC article. Clinical Trial.
-
Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.J Infect Dis. 2017 Dec 1;216(suppl_9):S824-S828. doi: 10.1093/infdis/jix413. J Infect Dis. 2017. PMID: 29040621 Free PMC article. Review.
References
-
- Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. Aids. 2008;22:973–981. - PubMed
-
- Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32:293–311. - PubMed
-
- Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007:CD003510. - PubMed
-
- Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev. 2005:CD005479. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K01 RR000188/RR/NCRR NIH HHS/United States
- M01 RR000645/RR/NCRR NIH HHS/United States
- RR000188/RR/NCRR NIH HHS/United States
- K24 RR016482/RR/NCRR NIH HHS/United States
- M01 RR000188/RR/NCRR NIH HHS/United States
- RR000645/RR/NCRR NIH HHS/United States
- U01 DA015053/DA/NIDA NIH HHS/United States
- U01 AI034841/AI/NIAID NIH HHS/United States
- U01 HD041983/HD/NICHD NIH HHS/United States
- P30 AI060354/AI/NIAID NIH HHS/United States
- U01 AI-38858/AI/NIAID NIH HHS/United States
- U01 AI034858/AI/NIAID NIH HHS/United States
- U01 DA015054/DA/NIDA NIH HHS/United States
- N01 AI085339/AI/NIAID NIH HHS/United States
- U01 HD036117/HD/NICHD NIH HHS/United States
- P30 AI60354/AI/NIAID NIH HHS/United States
- U01 AI038858/AI/NIAID NIH HHS/United States
- U01 AI068636/AI/NIAID NIH HHS/United States
- K24 RR16482/RR/NCRR NIH HHS/United States
- U01 AI050274/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous